ALK and Grandpharma team up to market the first adrenaline autoinjector in China
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) to launch its adrenaline autoinjector (AAI), Jext, in China via a partnership with leading supplier of adrenaline, Grandpharma.
- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) to launch its adrenaline autoinjector (AAI), Jext, in China via a partnership with leading supplier of adrenaline, Grandpharma.
- ALK will receive upfront and registration milestone payments totalling EUR 12 million (~DKK 90 million) in return for granting Grandpharma the exclusive rights to Jext in China.
- ALK will also manufacture and supply Jext and receive revenue from the sale of products to Grandpharma.
- Grandpharma is the leading supplier of adrenaline ampoules in China today and the company has extensive commercial reach within clinics and emergency care.